Immunotherapy using monoclonal antibodies -checkpoint inhibitors -is a dynamically evolving discipline of clinical oncology and a new hope for patients with advanced and disseminated cancer. However, the activation of T-lymphocytes can at the same time lead to autoimmune response and destruction of healthy organs, which is a serious adverse effect that can also affect the endocrine system. Here we present possible endocrine complications of immunotherapy with contemporary inhibitors of immune checkpoints (CTLA-4, PD-1, PD-L1/L2), their frequency, symptoms, and proposed grade-dependent treatment. Failure to diagnose endocrine pathology can in adverse circumstances lead to treatment failure and condemn the patient's fate. Due to tremendous progress in cancer immunotherapy during the last few years and an increase in the number of treated patients, endocrinologists should become acquainted with the specificity of this mode of oncological treatment. (Endokrynol Pol 2018; 69 (6): 722-733)
Introduction
For many years scientists have tended to use the inner forces of the immune system to fight diseases. Cancer has not been an exception; however, it was not until the introduction of monoclonal antibodies inhibiting immune checkpoints that a breakthrough in this field was made [1, 2] .
This novel therapy was first used to fight melanoma (ipilimumab -monoclonal antibody anti-CTLA-4, FDA approved in 2011). Subsequently, numerous attempts were made to use antibodies against novel molecules, as well as to cure other cancer types, including renal cancer, non-small-cell lung cancer, head and neck cancer, haematological neoplasms, etc. The American Society of Clinical Oncology recognised immunotherapy as the greatest achievement of 2015, 2016, and 2017 in cancer treatment. The number of clinical trials in this field indicates the growing interest and great hope attributed to this type of treatment [3] .
On the other hand, immune system activation, being the effect of the therapy, can at the same time lead to major complications, including endocrine system disorders. Adverse reactions depend on the medication used as well as individual predisposition. Their first symptoms are often non-characteristic and tend to be attributed to the underlying disease. Knowledge of possible endocrine complications of immunotherapy is necessary to ensure the patients' safety, and due to their growing number it is necessary for every endocrinologist.
Immunotherapy using inhibitors of immune response checkpoints
A healthy human body can effectively fight foreign cells, including cancer cells. Cancer cells can escape immune surveillance by inhibiting the immune response and becoming invisible to the immune system. For over 100 years attempts have been made to use the patient's immune system to fight cancer, unfortunately without any major progress. Only during the last few years has precise knowledge about the roles of each of the complicated immune reaction participants allowed the rise of contemporary immunotherapy. Immunocompetent cells, their roles and interactions, as well as the mechanisms of escape from immune surveillance have only recently been understood. This knowledge, gained in the last years, has facilitated therapy based on monoclonal antibodies blocking the checkpoints of immune response. For its action, the immune system needs either an effective mechanism of response induction or its limitation to avoid the threat of overreaction, which could be worse than the illness itself. The identification of the molecules that limit the immune response (immune response checkpoints) has enabled the invention of drugs that can effectively unlock the immune system and consequently restore efficient inner immune reactions. That achievement became the breakthrough event of contemporary immunotherapy [4] .
T-lymphocyte activation leads to an increased expression of proteins able to inhibit their excess action.
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These proteins are called immune checkpoints. One of them is CTLA-4 (cytotoxic T-cell antigen-4), discovered in 1987. Its ligands are CD80 and CD86, molecules that are present on the surface of antigen-presenting cells (APCs). Weak CTLA-4 expression is connected with increased autoimmune diseases incidence [5] [6] [7] , including autoimmune thyroid disorders [8, 9] . Monoclonal antibody directed against CTLA-4 was the first immune checkpoint inhibitor used to treat melanoma in clinical trials initiated in 2007 [10] and registered by FDA in 2011.
Another immune checkpoint protein is PD-1 (programmed death receptor-1), expressed on T-lymphocytes, B-lymphocytes, as well as monocytes/macrophages. Overly increased action of T-lymphocytes against their own tissues is inhibited by binding the protein with its ligands (PD-L1 and PD-L2) present on the surface of its own cells. These ligands were also found on the cancer cell surface, allowing them to escape the immune system response. Their presence also allowed for treatment based on the inhibition of either PD-1 (e.g. nivolumab, pembrolizumab) or PD-L1 (e.g. atezolizumab, durvalumab). These drugs given alone or together with CTLA-4 inhibitor nowadays constitute important treatment regimens in melanoma, renal cell cancer, or non-small cell lung cancer (Fig. 1) . The efficacy of antibodies to PD-1 or PD-L1 is dependent on the presence of respective surface proteins on cancer cell. The mutation load is also an important response prognostic factor. Generally, the more mutations, immunogenic neo-antigens, microsatellite instability (MSI), and deficiency DNA mismatch repair (dMMR), the more frequent and longer the response to the treatment [11, 12] .
Other trials that are still ongoing focus on different lymphocyte surface molecule inhibitors such as TIM-3 and LAG-3, or agonists of co-stimulatory proteins that can prove their effectiveness in the future [13, 14] .
Immune-related adverse events (irAEs)
Immune-related adverse events (IrAEs) can potentially affect all organs. The toxicity of immunotherapy is different in its nature from other anti-cancer therapies. It is specifically connected with the mechanism of the treatment involving stimulation of the immune response, infiltration of the organs by the activated T-lymphocytes, and targeted, specific autoimmune reaction. Due to the presence of immune checkpoints in the whole organism, the adverse reactions can also be present in every organ. The most frequent are the complications involving skin, gastro-intestinal tract (including liver), endocrine glands, more seldom osteoarticular, respiratory, cardiovascular, and nervous system as well as kidneys and different elements of the eye. Their frequency and grade depend on numerous factors connected with either the therapy (the medication used, combined therapy) or the patient (expression of the target checkpoint protein, individual characteristics, status of the immune system before commencing the therapy, pre-existing autoimmune conditions) [15] . The trials on pre-treatment identification of possible future therapy-driven adverse outcomes, defining possible predicting biomarkers to identify at-risk patients and enable early adverse reaction detection, are still ongoing [16, 17] . Additionally, trials on the influence of external factors, such as diet, smoking status, or gut microbiome, are also in progress [18, 19] .
As already mentioned, immunotherapy complications can manifest with great variation in terms of location, frequency, and time from commencing the treatment. The adverse events toxicity grade (generally 
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assessed according to CTCAE -Common Terminology Criteria for Adverse Events, which will be discussed further below) determines actions needed to be undertaken, including in some cases the cessation of therapy [20] [21] [22] [23] .
The most frequent AEs are skin reactions such as itching, rash, vitiligo, photosensitivity, alopecia, and others. They are the first to appear (2-3 weeks from the start of treatment) in more than 50% of patients. They manifest more frequently during the treatment with CTLA-4 inhibitors. Most of them are benign and resolve after applying antihistamines or corticosteroids and do not require the discontinuation of treatment.
The adverse reactions in the alimentary system (diarrhoea, abdominal pain, vomiting, intestinal mucous inflammation) are frequent, with varying grades. They appear predominantly during combined treatment with anti-CTLA-4 and anti-PD-1 antibodies, affecting 45% of patients. In high-grade reactions or in the case of colitis, they require discontinuation of treatment, intravenous administration of corticosteroids, and, in some cases, immunosuppressive drugs. These kinds of complications are significantly less frequent during treatment with novel anti-PD-L1 inhibitors (e.g. for durvalumab they appear in only 2%) [24] [25] [26] .
The liver complications should be sought for and monitored during each cycle of therapy, as they are frequent and initially asymptomatic. SGOT and SGPT assay is sufficient. The complications appear in 5-10% of patients during monotherapy and 25-30% of patients on combined therapy.
The next group comprise endocrine complications, which are thoroughly described in the next section. They appear in about 10% of patients with great diversity depending on the specific drugs and the gland involved. In general, they have non-characteristic initial presentation and unnoticeable course until serious complications with long-lasting reconvalescence or even definite dysfunction of involved organs requiring hormonal substitution.
Musculoskeletal or rheumatologic complications were described in 2 to 12% of treated patients, usually as vasculitis, inflammatory arthritis, or myositis of benign nature. They usually resolve quickly after treatment with corticosteroids.
Less frequent are the complications involving lungs (including interstitial inflammation), kidneys (frequently only manifesting as abnormal GFR), and nervous system (less than 1% of treated patients) involving polyneuropathy, optic nerve inflammation, Guillian-Barre syndrome, myasthenia, and aseptic meningitis. Rarely, adverse reactions involve the heart (e.g. rhythm perturbation with clinical course similar to myocarditis or cardiomyopathy), pancreas, and eyes (keratitis, uveitis, conjunctivitis, episcleritis).
There are observations that the appearance of side effects during the immunotherapy (unless, of course, they require the discontinuation of therapy) can indicate greater efficacy of the treatment. The prospective trials on the correlation between AE incidence and the treatment efficacy are still ongoing [20] [21] [22] [23] 27] .
The endocrine adverse reactions
The endocrine adverse reactions during immunotherapy are frequent and appear usually after 7-20 weeks. Immunotherapy involving anti-CTLA-4 or combined therapy involving the antibody can evoke hypopituitarism due to hypophysitis, whereas during anti-PD-1 and anti-PD-L1/L2 therapy thyroid disorders (mainly hypothyroidism) are often observed. Each endocrine organ can be affected by AEs, including the adrenal cortex (either secondary or primary, life threatening insufficiency), which is essential for patient health. Less frequent are type 1 diabetes and hypoparathyroidism [28] .
An important feature of endocrine complications is their non-characteristic initiation, frequently attributed to the underlying disease itself. One has to keep in mind that, contrary to the everyday practice, one is not dealing with a previously healthy patient in whom the symptoms appear instantly. Here the first symptoms such as fatigue, weakness, loss of appetite, and change in body mass can be attributed to the underlying cancer [28, 29] . Hence one should actively seek the symptoms of hormonal dysfunction, especially taking precise history during each cycle and ordering additional biochemical tests when needed.
As mentioned above, the intensity of the adverse reaction is generally assessed according to Common Terminology Criteria for Adverse Events (CTCAE) scaling from 1 to 5 (latest version 5.0 dated November 27, 2017). Grade 1 denotes nonsymptomatic deviation in a laboratory test, grade 2 -moderate symptoms, grade 3 -severe symptoms frequently requiring admission to the hospital, grade 4 means life-threatening adverse reaction, and grade 5 -death due to AE. Endocrine AEs are usually classified as grade 1-2 and do not require definite discontinuation of immunotherapy. Nevertheless, a lot of patients suffer from serious AEs, particularly in the case of late diagnosis, which can possibly result in the necessity of immunotherapy discontinuation and the therapy with high dose corticosteroids or can even pose a life-threatening condition (1-2% of patients) [28] .
Pituitary complications
Pituitary dysfunction as a complication of immunotherapy affects 1.5-17% of patients treated with an-
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ti-CTLA-4 antibody alone or in combination with other medications. It appears more often in men and in the elderly. The symptoms appear usually after two months of treatment and can be the result of the mass effect caused by pituitary gland enlargement (headache, vision disturbances) or insufficient hormone production (fatigue, tiredness, loss of appetite). Local symptoms require excluding brain metastases and aseptic meningitis [30, 31] . In most patients, characteristic presentation in MRI is seen. The pituitary gland is enlarged as a result of infiltration by immunocompetent cells [32, 33] . Laboratory results usually show changes typical for anterior lobe insufficiency for all axes. Isolated GH or PRL deficiency is seen less frequently. Posterior lobe insufficiency has not been observed in this setting. Every toxicity above grade 2, meaning the presence of local symptoms or hormonal deficiency, requires the interruption of immunotherapy. In the case of mass effect, particularly vision problems, urgent therapy with intravenous steroids is required (e.g. hydrocortisone 50-100 mg 3-4 times a day or an equivalent dose of methylprednisolone). In moderately severe symptoms oral corticosteroids are usually enough (e.g. hydrocortisone 20-30 mg in split doses or prednisone/prednisolone in equivalent dose). Substitution therapy with respective hormones should be used, in the same manner as in other forms of hypopituitarism. Long lasting hormonal deficiency is typical for this form of hypopituitarism, despite discontinuation of the therapy and resolution of the lesions seen in MRI. This particularly applies to adrenal insufficiency and, to a lesser extent, to thyroid and gonads, and consequently leads to prolonged necessity of hormonal substitution.
Hypopituitarism appears incidentally as a consequence of anti-PD-1 or anti-PD-L1 therapy in less than 1% of treated patients (in durvalumab therapy less than 0.1%). Therefore, pituitary complications should be mainly expected during treatment with ipilimumab alone or in combination with other drugs [28, 30, 31, 34] .
Disorders of thyroid function during immunotherapy
Aberrant thyroid function, mainly hypothyroidism, is frequent (> 10% treated) during PD-1 and PD-L1/L2 inhibitor therapy (nivolumab, pembrolizumab, atezolizumab, durvalumab). During anti-CTLA-4 treatment such complications depend on the dose and are seen in 1-5% patients on standard dose or in up to 10% on ipilimumab 10 mg/kg. Combined therapy (e.g. ipilimumab + nivolumab) increases the risk to over 20%. One should remember about the possible occurrence of secondary hypothyroidism due to the abovementioned hypophysitis.
Thyroid-related adverse reactions encompass persistent or transient hypothyroidism, hyperthyroidism during painless thyroiditis, and manifestation of Graves' disease, including thyrotoxic crisis or orbitopathy. In most patients with thyroid complications concentrations of anti-thyroid antibodies (anti-TPO and anti-TG) are elevated. However, their role as risk factors for incidence of thyroid dysfunction or its duration has not yet been confirmed.
The time from the beginning of immunotherapy until the manifestation of thyroid dysfunction varies from several days to over a year, with median value of ca. three months. The complications appear more often in women, in most cases are classified as grade 1 or 2, and do not require discontinuation of immunotherapy.
Considering treatment options, one should take into account symptoms and hormonal test results. In the case of asymptomatic TSH elevation below 10 uIU/ml, thyroxine substitution as well as immunotherapy discontinuation is not necessary; however, close monitoring of thyroid function is advised before each cycle. The cause of hyperthyroidism should be differentiated between Graves' disease and destructive inflammation. The assessment of thyroid antibodies, including anti-TSH receptor antibodies and thyroid scintigraphy, is suggested as well as diagnosis-dependent treatment (glucocorticoids, betablockers, less frequently anti-thyroid drugs).
One should also keep in mind the possibility of secondary hypothyroidism occurrence due to hypopituitarism, and in each case of low TSH accompanying low fT4 the pituitary-adrenal axis should be assessed.
Primary hypo-or hyperthyroidism is often transient and often requires follow-up laboratory testing both during and after treatment or medication change [28, 35, 36] .
Immunotherapy-induced adrenal insufficiency
Adrenal insufficiency can be the first manifestation of hypopituitarism during immunotherapy. Its frequency is comparable with hypopituitarism itself because it appears in 75% of such patients.
Immunotherapy can also cause primary adrenal insufficiency, although less frequently (up to 2%; in the majority of trials less than 1%). The first sign of imminent adrenal insufficiency is frequently asymptomatic hyponatraemia, which makes routine serum electrolyte testing mandatory.
Adrenal complications in most patients require discontinuation of immunotherapy because in the SZKOLENIE PODYPLOMOWE majority of them the toxicity reaches grade 3, requiring admission to the hospital. In some patients, adrenal enlargement was observed in imaging studies, fulfilling criteria for adrenalitis. The treatment is typical for primary adrenal insufficiency. One should not forget mineralocorticoid supplementation [28, 36] .
Other, less frequent endocrine complications
Diabetes is a rare complication of immunotherapy. Its incidence in this setting is below 1%, mainly in patients treated with anti-PD-1 antibody (e.g. nivolumab 0.9%, pembrolizumab 0.2%, avelumab 0.1%). It usually reaches grade 3 with glucose concentration above 250 mg%, requiring interruption of immunotherapy and administration of insulin, as in type 1 diabetes.
There are single case reports describing other adverse effects, like acute hypocalcaemia as a consequence of hypoparathyroidism during combined treatment with ipilimumab and nivolumab [37] [38] [39] .
Cooperation between the endocrinologist and oncologist
Therapy with immune checkpoints inhibitors is administered in specialised oncological centres (about 20 centres currently in Poland). The patients are supervised by clinical oncologists, who are responsible for proper qualification and safe treatment, including early and pertinent recognition of adverse effects. Drug programs contain requirements to perform screening laboratory tests, related also to endocrine function, which help to detect the most frequent complications. As was mentioned earlier, some grade 1 and 2 complications do not require treatment. Often the oncologist him/herself orders the treatment, as in the case of benign primary hypothyroidism. In centres where specialist consultation is possible, the patient can be attended to by a multidisciplinary team. That can be a great support for clinical oncologists, especially in difficult cases requiring extensive knowledge and experience in a specific field. The patient with full-blown hypopituitarism or primary adrenal insufficiency should certainly be treated by an endocrinologist. The decision concerning discontinuation of immunotherapy or its postponement is at the discretion of the oncologist, but the opinion of the endocrinologist in this case is crucial.
As mentioned, a lot of endocrine complications of immunotherapy are permanent, meaning that irrespective of the termination, interruption, or change in oncologic therapy the substitution therapy will be supervised by the patient's endocrinologist.
Conclusions
It is our hope that future advancements in immunotherapy will bring medications with fewer adverse effects. However, the frequent administration of combined therapy and broadening of indications to use the therapy in other cancers cause the number of treated patients to increase rapidly. In the near future both oncologists and endocrinologists will have to face many incidents of treatment-related endocrinopathy. It is essential for specialists from both fields to band together and come up with combined therapies for the greater good of the patients.
Although currently the problem of endocrine complications of immunotherapy seem distant and irrelevant for many endocrinologists, immunotherapy with all its prospective advantages and threats is right on our doorstep, and we have to be prepared. 
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Streszczenie
Immunoterapia z użyciem przeciwciał monoklonalnych -inhibitorów punktów kontroli immunologicznej -jest dynamicznie rozwijającą się dziedziną onkologii klinicznej, szansą dla wielu chorych z zaawansowaną i uogólnioną chorobą nowotworową. Aktywacja układu odpornościowego w zakresie czynności limfocytów T może równocześnie doprowadzić do reakcji autoimmunizacyjnej, niszczenia zdrowych narządów i do poważnych działań niepożądanych, w tym dotyczących układu wydzielania wewnętrznego. W przedstawianej pracy omówiono możliwe powikłania endokrynne immunoterapii z użyciem obecnie stosowanych inhibitorów punktów kontroli immunologicznej (CTLA-4, PD-1, PD-L1/L2) z uwzględnieniem rodzaju i częstości działań niepożądanych, objawów oraz postępowania w zależności od stopnia toksyczności. Brak właściwego rozpoznania patologii dotyczącej układu hormonalnego może w niekorzystnych okolicznościach zadecydować o ostatecznym niepowodzeniu leczenia i przesądzić o losie chorego. Z uwagi na gwałtowny w ostatnich latach postęp w dziedzinie immunoterapii należy spodziewać się rosnącej liczby leczonych chorych. Perspektywa ta wymusza na nas, specjalistach endokrynologach, poznanie tej nowej i ważnej strategii leczenia onkologicznego. 
Wstęp
Naukowcy od wielu lat starali się wykorzystać możliwo-ści własnego układu odpornościowego pacjenta do walki z chorobami, w tym nowotworami. Dopiero jednak zastosowanie w leczeniu przeciwciał monoklonalnych, tak zwanych inhibitorów punktów kontroli immunologicznej, przyniosło przełom w immunoterapii [1, 2] . Po raz pierwszy zastosowano nowy rodzaj terapii w leczeniu czerniaka (przeciwciało monoklonalne anty-CTLA-4 pod nazwą ipilimumab zaaprobowane przez U.S. Food and Drug Administration [FDA] w 2011 roku), a w kolejnych latach prowadzono liczne próby z użyciem przeciwciał przeciw nowym molekułom i w leczeniu kolejnych typów nowotworów, zwłaszcza raka nerki, niedrobnokomórkowego raka płuca, nowotworów głowy i szyi, w hematoonkologii i wielu innych. Amerykańskie Towarzystwo Onkologii Klinicznej (ASCO, American Society of Clinical Oncology) uznało immunoterapię za największe osiągnięcie lat 2015, 2016 i 2017 w zakresie walki z chorobami nowotworowymi. Liczba toczących się badań klinicznych oraz międzynarodowych konferencji wskazuje na ogromne zainteresowanie tematem w środowisku lekarskim i wielką nadzieję z nim związaną [3] .
Aktywacja układu odpornościowego, będąca sednem leczenia, może prowadzić równocześnie do licznych powikłań narządowych, w tym dotyczących układu wydzielania wewnętrznego. Objawy uboczne zależą zarówno od rodzaju leku, jak i od indywidualnej predyspozycji chorego. Ich wstępne symptomy bywają niecharakterystyczne i mogą być przypisywane chorobie podstawowej. Znajomość możliwych powikłań endokrynnych immunoterapii jest konieczna dla bezpiecznego jej prowadzenia, a wobec rosnącej liczby leczonych chorych wiedza ta staje się niezbędna dla każdego endokrynologa. To właśnie odkrycie inhibitorów punktów kontroli immunologicznej stanowi przełom we współczesnej immunoterapii [4] . Aktywacja limfocytów T powoduje zwiększenie ekspresji na ich powierzchni białek odpowiedzialnych za hamowanie nadmiernej, a więc szkodliwej dla organizmu, aktywności układu odpornościowego. Białka te nazwano punktami kontroli immunologicznej (immune checkpoints). Należy do nich między innymi białko CTLA-4 (cytotoxic T cell antygen-4) zidentyfikowane w 1987 roku. Ligandami dla CTLA-4 są -występujące na powierzchni komórek prezentujących antygen -cząsteczki CD80 i CD86. Słaba ekspresja CTLA-4 wiąże się z częstszym występowaniem chorób o podłożu autoimmunizacyjnym [5] [6] [7] , w tym autoimmunizacyjnych chorób tarczycy [8, 9] .
Przeciwciało monoklonalne skierowane przeciwko CTLA-4 było pierwszym lekiem z grupy inhibitorów punktów kontroli immunologicznej wprowadzonym do leczenia, zastosowano je w leczeniu rozsianego czerniaka po raz pierwszy w ramach badań klinicznych w 2007 roku [10] i pod nazwą ipilimumab zostało przez FDA zaaprobowane w 2011.
Innym białkiem powierzchniowym będącym punktem kontroli immunologicznej jest PD-1 (programmed death receptor-1) ulegający ekspresji w limfocytach T, limfocytach B i monocytach/makrofagach. Nadmierna aktywność limfocytów T wobec własnych tkanek jest hamowana poprzez wiązanie PD-1 z jego ligandem (PD-L1 lub PD-L2) obecnym na powierzchni komórek własnych organizmu. Obecność tego ligandu wykryto również na powierzchni komórek nowotworowych, co pozwala nowotworowi na ucieczkę przed nadzorem immunologicznym, a z drugiej strony pozwoliło na leczenie oparte o blokowanie zarówno PD-1 (np. niwolumab, pembrolizumab), jak i PD-L1 (np. atezolizumab, durwalumab). Leki będące inhibitorami obu wyżej wymienionych białek, w tym skojarzone leczenie z CTLA-4, stanowią obecnie podstawowe sposoby leczenia czerniaka, raka nerki czy niedrobnokomórko-wego raka płuca (ryc. 1). Skuteczność immunoterapii z użyciem przeciwciał wobec PD-1 i PD-L1 jest zwią-zana z ekspresją właściwego białka powierzchniowego na komórce nowotworu. Ważnym czynnikiem predykcyjnym jest również liczba mutacji w komórce guza. Zasadniczo, im większa liczba mutacji, neoantygenów nowotworowych o wysokiej immunogenności, czy też obecność niestabilności mikrosatelitarnej (MSI, microsatellite instability) lub tak zwanego deficytu naprawy błędnie sparowanych zasad azotowych w cząsteczce DNA (dMMR, mismatch repair deficient), tym częstsza i dłuższa odpowiedź na leczenie [11, 12] .
Trwają badania nad inhibitorami innych cząsteczek obecnych na powierzchni limfocytów m.in. TIM-3 i LAG-3, jak również nad agonistami białek kostymulujących, które w przyszłości mogą znaleźć zastosowanie w immunoterapii nowotworów [13, 14] .
Toksyczność narządowa immunoterapii
Uboczne niekorzystne efekty immunoterapii dotyczą potencjalnie wszystkich narządów. Jest to rodzaj toksyczności odmienny od obserwowanej po innych rodzajach leczenia przeciwnowotworowego, wiąże się specyficznie z mechanizmem zastosowanego leczenia opartego na odblokowaniu układu odpornościowe-go, infiltracją narządów aktywowanymi limfocytami T oraz ze specyficzną reakcją autoimmunizacyjną. Z uwagi na obecność punktów kontroli immunologicznej w całym organizmie, również niepożądane reakcje mogą dotyczyć każdego organu. Najczęstsze są w kolejności powikłania dotyczące skóry, układu
